Adjunctive Therapies in Severe Community-Acquired Pneumonia

  • Concepción Montón
  • Miquel Ferrer
Part of the Perspectives on Critical Care Infectious Diseases book series (CCID, volume 3)

Abstract

Community-acquired pneumonia (CAP) is a common illness that still presents substantial morbidity and mortality. In addition to empirical antibiotic therapy and to mechanical ventilatory support (if needed) there are several adjunctive therapies, targeted on reversing certain pathophysiological mechanisms that contribute to increased severity or are associated with complications during the evolution of severe CAP. This chapter reviews the adjunctive therapies currently available, with particular reference to: 1) inflammatory response modulation; 2) pharmacological modulation of abnormal gas exchange; and 3) the effects of body position on gas exchange.

Keywords

Placebo Toxicity Catheter Corticosteroid Pneumonia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10(Supp1.2):81–90.PubMedGoogle Scholar
  2. 2.
    Cavaillon JM. Cytokines in inflammation. CR Seances Soc Biol. Fil; 1995:189:531–44.Google Scholar
  3. 3.
    Meduri GU, Chroussos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest. 1998;114:355–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson J. Role of glucocorticosteroids in the treatment of infectious diseases. Eur J Clin Microbiol Infect Dis. 1993;12 (Supp1.1):68–72.CrossRefGoogle Scholar
  5. 5.
    McGowan JE, Chesney PJ, Crossley KB, La Force FM. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J Infect Dis 1992;165:1–13.PubMedCrossRefGoogle Scholar
  6. 6.
    The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis Pneumonia in the Acquired Immunodeficiency Syndrome. N Engl J Med. 1990;323:1500–4.CrossRefGoogle Scholar
  7. 7.
    Huang ZB, Eden E. Effect of corticosteroids on IL-lb and TNF-a release by alveolar macrophages from patients with AIDS andPneumocystis cariniiPneumonia. Chest. 1993;104:751–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Perenboom RM, Sauerwein RW, Beckers P, Van Schijndel ACHW, Van Steenwijk RP, Borleffs JCC, Van Leusen R, Van der Meer JWM. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seropositive patients with Pneumocystis carinii Pneumonia. Eur J Clin Invest. 1997;27:333–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Montón C, Torres A, El-Ebiary M, Filella X, Xaubet A, Puig de la Bellacasa J. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Crit Care Med. 1999; (in press).Google Scholar
  10. 10.
    Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest. 1998;114:426–31.PubMedCrossRefGoogle Scholar
  11. 11.
    De Boisblanc BP, Summer WR, Mason C, Shellito J, Logan E, Bear M, Johnson S, Nelson S. Phase I trial of Granulocyte colony-stimulating factor in severe community-acquired pneumonia. Am Rev Respir Dis 1993;147:A204.Google Scholar
  12. 12.
    Nelson S, Farkas S, Fotheringham N, Ho H, Marrie T, Movahled H. Filgastrim in the treatment of hospitalized patients with community-acquired pneumonia (CAP). Am J Respir Crit Care Med. 1996;153:A535.Google Scholar
  13. 13.
    Wunderink RG, Leeper KV, Schein RMH, Nelson S, DeBoisblanc B, Baker F, Fotheringam N, Logan E. Clinical response to Filgastrim (r-metHu G-CSF) in pneumonia with severe sepsis. Am J Respir Crit Care Med. 1996;153A:l23.Google Scholar
  14. 14.
    Gea J, Roca J, Torres A, Agustí AGN, Wagner PD, Rodriguez-Roisin R. Mechanisms of abnormal gas exchange in patients with pneumonia. Anesthesiology 1991;75:782–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Mélot C. Contributions of multiple inert gas elimination technique to puhnonary medicine: 5- Ventilation-perfusion relationships in acute respiratory failure. Thorax. 1994;49:1251–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Graham LM, Vasil A, Vasil ML, Voelkel NF, Stenmark KR. Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Respir Dis. 1990;142:221–9.PubMedGoogle Scholar
  17. 17.
    Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis Cobo E, Rodriguez-Roisin R. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144:312–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Reilo J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest. 1993;103:232–5.CrossRefGoogle Scholar
  19. 19.
    Gerber JG, Voelkel N, Nies AS, McMurtry IF, Reeves IT. Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of prostaglandin I2. J Appl Physiol. 1980;49:107–12.PubMedGoogle Scholar
  20. 20.
    Light RB. Indomethacin and acetylsalicylic acid reduce intrapulmonary shunt in experimental pneumococcal pneumonia. Am Rev Respir Dis. 1986;134:520–5.PubMedGoogle Scholar
  21. 21.
    Hanly PI, Roberts D, Dobson K, Light RB. Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet. 1987;1:351–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Ferrer M, Tones A, Baer R, Hernandez C, Roca J, Rodriguez-Roisin R. Effect of acetylsalicylic acid no pulmonary gas exchange in patients withseverepneumonia. Chest. 1997; 111: 1094–100.PubMedCrossRefGoogle Scholar
  23. 23.
    Walmrath D, Schenider T, Pilch J, Schermuly R, Grirnminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med. 1995;151:724–30.PubMedGoogle Scholar
  24. 24.
    Melot C, Naeije R, Rothschild T, Mertens P, Mols P, Hallemans R. Improvement in ventilation-perfusion matching by almitrine in COPD. Chest. 1983;83:528–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Reyes A, Roca J, Rodriguez-Roisin R, Torres A, Ussetti P, Wagner PD. Effect of ahnitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis. 1988;137:1062–7.PubMedGoogle Scholar
  26. 26.
    Dreyfuss D, Djedaini K, Lanore JJ, Mier L, Froidevaux R, Coste F. A comparative study of the effects of almitrine bismesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia. Am Rev Respir Dis 1992;146:295–9.PubMedGoogle Scholar
  27. 27.
    Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Rossaint R, Falke KR, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399–405.PubMedCrossRefGoogle Scholar
  29. 29.
    Gómez F, Iglesia R, Tones A, Cabello H, Barberà JA, Roca J, Nicolás JM, Rodriguez-Roisin R. Nitric oxide inhalation in severe pneumonia. Eur Respir J. 1997;10:21s.Google Scholar
  30. 30.
    Fishman AP. Down with the good lung. N Engi J Med. 1981;304:537–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Concepción Montón
    • 1
  • Miquel Ferrer
    • 2
  1. 1.Pneumologia. Corporació Sanitària Parc Taulí. SabadellBarcelonaSpain
  2. 2.Institut Clínic de Pneumologia i Cirurgia ToràcicaHospital ClinicBarcelonaSpain

Personalised recommendations